The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma
返回论文页
Short communication|更新时间:2024-02-04
|
The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma
Zhouliang Bian, Benhong Gu, Guohai Shi, et al. The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma. [J]. Genes & Diseases 1(1):80-83(2024)
DOI:
Zhouliang Bian, Benhong Gu, Guohai Shi, et al. The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma. [J]. Genes & Diseases 1(1):80-83(2024) DOI: 10.1016/j.gendis.2023.02.036.
The single-cell landscape reveals unique tumor subsets and microenvironments associated with poor clinical outcomes in primary testicular diffuse large B-cell lymphoma
摘要
Abstract
关键词
Keywords
references
1 M. Pollari, S.K. Leivonen, S. LeppäTesticular diffuse large B-cell lymphoma-clinical, molecular, and immunological features Cancers, 13 (16) (2021), p. 4049
2 H. Takahashi, N. Tomita, M. Yokoyama, et al.Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era Cancer, 118 (17) (2012), pp. 4166-4172
3 L. Venturutti, A.M. MelnickThe dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs Blood, 136 (20) (2020), pp. 2263-2274
4 C.B. Steen, B.A. Luca, M.S. Esfahani, et al.The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma Cancer Cell, 39 (10) (2021), pp. 1422-1437
5 Z.Y. Xu-Monette, M.B. Møller, A. Tzankov, et al.MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program Blood, 122 (15) (2013), pp. 2630-2640